BPC-157 (Body Protection Compound-157)

Also referred to as Body Protection Compound-157, PL 14736.

Status: Investigational. BPC-157 is not an FDA-approved drug product for any indication, and essentially all published work on it is preclinical, meaning animal or cell studies rather than controlled human trials. In 2023 the FDA placed BPC-157 in the category of bulk substances it identified as raising significant safety risks for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, a determination that restricts how compounding pharmacies may handle it. That determination reflects the absence of adequate safety data in humans, not a finding that the peptide is safe outside a research setting. Anyone encountering BPC-157 marketed for sale should treat that as a regulatory red flag rather than a sign of legitimacy.

BPC-157 is a synthetic peptide derived from a fragment of a protein found in gastric juice, studied almost exclusively in animal and cell models of tissue and gut signalling. It is not an FDA-approved drug product, and in 2023 the FDA identified it as a bulk substance raising significant safety concerns for compounding, which limits how it can lawfully be prepared. Enthusiasm for BPC-157 online is driven overwhelmingly by preclinical findings and anecdote rather than by controlled human trials. Patients who ask about it should understand that its popularity currently exceeds the strength of its human evidence base by a wide margin.

What it is

BPC-157 (short for Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence originally identified as a partial fragment of a protein present in human gastric juice. It is not derived from a naturally circulating hormone and is not manufactured as an approved pharmaceutical. Laboratory versions used in research are chemically synthesized peptides rather than extracts of any FDA-cleared product.

Why people ask about it

Patients typically encounter BPC-157 through fitness and recovery forums, where it is discussed as a research compound linked to tendon, ligament, and gut healing in animal studies. The gap between how it is marketed online and what has actually been demonstrated in humans is part of why physicians want to discuss it directly rather than let a patient rely on secondhand claims. Some ask because they have already purchased it from an unregulated source and want an honest read on the evidence.

Proposed mechanism

The mechanisms proposed for BPC-157 come almost entirely from rodent and cell-culture experiments, not from human pharmacology studies. Researchers have proposed effects on angiogenesis, growth factor expression, and nitric oxide signalling pathways relevant to tissue and gut lining repair processes in these models. Some animal work also proposes effects on the vagal-nerve-mediated gut-brain axis. None of these proposed mechanisms have been confirmed in adequately controlled human pharmacokinetic or pharmacodynamic studies, and it is not established that findings in rodent tissue translate to human physiology at any exposure level.

What researchers have studied

• Rodent models of tendon and ligament injury
• Rodent and rat models of gastric and intestinal lining injury
• Cell-culture studies of fibroblast and endothelial cell migration
• Animal models of nerve injury and vagal signalling
• Structure-activity work characterizing the peptide fragment itself

Human evidence

• No adequately controlled human clinical trials of BPC-157 for any indication have been identified in the peer-reviewed literature.
• Reports of human use are almost entirely anecdotal, self-reported, or drawn from unregulated online sourcing rather than clinical research settings.
• Because there is no established human dosing or safety profile, statements about effectiveness or safety in people are extrapolations from animal data, not demonstrated findings.
• The absence of human trials means long-term safety, immunogenicity, and interaction risks in people remain essentially uncharacterized.

Preclinical evidence

• Rat models have reported accelerated healing markers in tendon and ligament injury.
• Rodent studies have reported protective effects on gastric mucosa in models of induced ulceration.
• Cell-culture experiments have reported increased migration of fibroblasts and endothelial cells exposed to the peptide.
• Animal models have reported effects on nerve regeneration following induced injury.
• All of the above are laboratory or animal findings and have not been replicated in controlled human studies.

What is not yet known

• Whether any preclinical finding translates into a measurable benefit in humans at any exposure level.
• What an appropriate human exposure range would be, since none has been established in controlled trials.
• Long-term safety, including effects with repeated or extended exposure in people.
• How BPC-157 interacts with other medications or existing health conditions in humans.
• The purity, identity, and consistency of unregulated products marketed under this name.
• Whether the FDA's 2023 bulk-substance action will change over time as more data becomes available.

Regulatory status and access

Because of the FDA's 2023 bulk-substance safety determination, BPC-157 is not something a compounding pharmacy can generally prepare as a standalone prescription item, and its presence here reflects an ingredient a physician may discuss in the context of a broader, physician-selected formulation rather than an individually available product. Compounding, where it occurs elsewhere, is never the same as FDA approval. Ask about current availability. A physician determines medical appropriateness only after a full evaluation.

Known and potential risks

• No established human safety profile exists, so risks of allergic reaction, immune response, or organ effects are not well characterized.
• Products sold online as BPC-157 are frequently unregulated, with no assurance of correct identity, purity, or sterility.
• The FDA's 2023 safety determination reflects real regulatory concern about compounding this substance, not a cleared path to safe use.
• Any injectable research-grade product carries injection site and contamination risks when not compounded under pharmaceutical quality controls.
• Interaction risk with other medications is essentially unstudied in humans.
• Marketing claims of healing or recovery benefits are not supported by human trial evidence and should be treated skeptically.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, given the complete absence of human safety data.
• Active or suspected malignancy, since effects on cell proliferation pathways have not been ruled out.
• Undiagnosed pain, gastrointestinal, or musculoskeletal symptoms that have not been medically evaluated.
• Known hypersensitivity to peptide compounds generally.
• Use alongside other unregulated research compounds without physician oversight.
• Reliance on this substance as a substitute for an evaluated, evidence-based treatment plan.

Questions to discuss with a physician

• What does the current lack of human trial data mean for me specifically?
• How did the FDA's 2023 bulk-substance determination change what a compounding pharmacy can legally prepare?
• What evidence-based alternatives exist for the tissue or gut concern I'm asking about?
• How would you evaluate the quality or legitimacy of a product marketed as BPC-157?
• What symptoms would mean I should stop and seek care immediately?
• Is there any legitimate research pathway through which this could become available to me?

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved drug product for any indication. In 2023 the FDA also placed it in a bulk-substance category identified as raising significant safety risks for compounding, which further restricts how it may be handled.

Does GOAL.MD sell BPC-157?

This page is educational. It does not describe a product for sale, and it should not be read as an offer or endorsement. Ask about current availability, and any decision about appropriateness rests with a physician after evaluation.

Has BPC-157 been tested in human clinical trials?

No adequately controlled human trials have been identified in the published literature. Nearly all available data come from rodent or cell-culture studies, which do not establish that the same effects occur in people.

What did the FDA actually say about BPC-157 in 2023?

The FDA identified BPC-157 as a bulk substance that raises significant safety risks in the context of compounding under section 503A, a formal step that restricts how compounding pharmacies may prepare it.

Why is BPC-157 so popular online if the evidence is this limited?

Much of its popularity traces to preclinical findings and anecdotal reports circulated in fitness communities, which can outpace what has actually been demonstrated in controlled human research.

Is BPC-157 safe?

Because no controlled human safety studies exist, a reliable safety profile has not been established. The FDA's 2023 action reflects genuine safety concern rather than reassurance.

What is BPC-157 derived from?

It is a synthetic peptide based on a fragment sequence identified in human gastric juice. It is manufactured synthetically rather than extracted from an approved biologic source.

Can a doctor prescribe BPC-157?

Given its regulatory status, it is not something a compounding pharmacy can generally prepare as a standalone prescription item. A physician can discuss the evidence and any legitimate context in which it might be relevant.

What should I do if I've already purchased BPC-157 online?

Discuss it openly with a physician, including the product source, so any relevant risks can be assessed. Unregulated products carry uncertainty about identity, purity, and sterility.

Are there human studies planned for BPC-157?

This page reflects the literature as currently checked; readers should verify the latest status directly, since preclinical interest does not assurance that human trials will follow.

What is BPC-157?

BPC-157 (short for Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence originally identified as a partial fragment of a protein present in human gastric juice. It is not derived from a naturally circulating hormone and is not manufactured as an approved pharmaceutical. Laboratory versions used in research are chemically synthesized peptides rather than extracts of any FDA-cleared product.

Does the legal or regulatory status of BPC-157 tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare BPC-157?

Because of the FDA's 2023 bulk-substance safety determination, BPC-157 is not something a compounding pharmacy can generally prepare as a standalone prescription item, and its presence here reflects an ingredient a physician may discuss in the context of a broader, physician-selected formulation rather than an individually available product. Compounding, where it occurs elsewhere, is never the same as FDA approval.

What human evidence exists for BPC-157?

No published controlled human trials were identified for the uses discussed here. No adequately controlled human clinical trials of BPC-157 for any indication have been identified in the peer-reviewed literature.

Have there been controlled human trials of BPC-157?

No adequately controlled human trial for the uses discussed here was identified. Anything presented elsewhere as a human result is an extrapolation from laboratory or animal work, or an anecdote.

What have animal and laboratory studies of BPC-157 reported?

Rat models have reported accelerated healing markers in tendon and ligament injury; Rodent studies have reported protective effects on gastric mucosa in models of induced ulceration; Cell-culture experiments have reported increased migration of fibroblasts and endothelial cells exposed to the peptide. These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for BPC-157 mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is BPC-157 proposed to work?

The mechanisms proposed for BPC-157 come almost entirely from rodent and cell-culture experiments, not from human pharmacology studies. Researchers have proposed effects on angiogenesis, growth factor expression, and nitric oxide signalling pathways relevant to tissue and gut lining repair processes in these models. This is a proposed pathway rather than a demonstrated effect.

What is BPC-157 being studied for?

Published work has focused on Rodent models of tendon and ligament injury; Rodent and rat models of gastric and intestinal lining injury; Cell-culture studies of fibroblast and endothelial cell migration; Animal models of nerve injury and vagal signalling. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about BPC-157?

Whether any preclinical finding translates into a measurable benefit in humans at any exposure level; What an appropriate human exposure range would be, since none has been established in controlled trials; Long-term safety, including effects with repeated or extended exposure in people; How BPC-157 interacts with other medications or existing health conditions in humans.

What are the risks of BPC-157?

No established human safety profile exists, so risks of allergic reaction, immune response, or organ effects are not well characterized; Products sold online as BPC-157 are frequently unregulated, with no assurance of correct identity, purity, or sterility; The FDA's 2023 safety determination reflects real regulatory concern about compounding this substance, not a cleared path to safe use.

Who should not consider BPC-157?

A physician would generally consider it inappropriate in these situations without specialist input: Pregnancy and breastfeeding, given the complete absence of human safety data; Active or suspected malignancy, since effects on cell proliferation pathways have not been ruled out; Undiagnosed pain, gastrointestinal, or musculoskeletal symptoms that have not been medically evaluated; Known hypersensitivity to peptide compounds generally.

Is BPC-157 appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

How does BPC-157 interact with other medications?

Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Interaction risk with other medications is essentially unstudied in humans.

What would a physician monitor if BPC-157 were discussed?

Monitoring concepts include Baseline evaluation of the underlying condition prompting interest in this substance; Ongoing clinical reassessment rather than reliance on self-reported online outcomes; Discussion of any new symptoms that could reflect an unrecognized reaction. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as BPC-157 verified?

No. Products sold online as BPC-157 are frequently unregulated, with no assurance of correct identity, purity, or sterility. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about BPC-157?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about BPC-157?

Useful questions include: What does the current lack of human trial data mean for me specifically?; How did the FDA's 2023 bulk-substance determination change what a compounding pharmacy can legally prepare?; What evidence-based alternatives exist for the tissue or gut concern I'm asking about?; How would you evaluate the quality or legitimacy of a product marketed as BPC-157?.

Why do people ask about BPC-157?

Patients typically encounter BPC-157 through fitness and recovery forums, where it is discussed as a research compound linked to tendon, ligament, and gut healing in animal studies. The gap between how it is marketed online and what has actually been demonstrated in humans is part of why physicians want to discuss it directly rather than let a patient rely on secondhand claims.

Who reviews what GOAL.MD publishes about BPC-157?

Clinical content is reviewed by a named physician for medical accuracy and by a second physician for regulatory and compliance language before it is published, and a review byline appears only when that review is recorded. New material stays unpublished until both reviews are on record.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.